CRL
Charles River Laboratories International, Inc.stockNYSE
At CloseNov 13, 2026 3:59:56 PM EST
338.04USD-0.813%(-2.77)838,318
Pre-marketNov 13, 2026 8:32:30 AM EST
342.46USD+0.484%(+1.65)
After-hoursNov 13, 2026 4:48:30 PM EST
340.00USD+0.580%(+1.96)
CRL Reddit Mentions by subreddit
Loading…
CRL Mentions × sentiment
Loading…
CRL Specific Mentions latest comments & posts
As of Friday, they had about $470,000,000 worth of SMMT (assuming they hadn't sold any over the past 4.5 months).
Friday night, SMMT got a CRL from the FDA. SMMT is gonna look ugly tomorrow.
Don't worry about Baker Brothers. They run a $20+ billion hedge fund, so it'll hurt, but not that much.
Also, look at the price action on SMMT on Friday (down 6+%), which makes me feel like the information leaked.
sentiment -0.342
Fair point. Summit's release says this CRL is for the BLA based on HARMONi, the trial in EGFR-mutated NSCLC after a TKI. HARMONi-3 is a separate trial in first-line NSCLC. Has Summit given a timing for the next HARMONi-3 update? I haven't seen a date from the company.
sentiment 0.318
Well, it might drop another 20%. But Harmoni 3 result gonna be more important than this CRL.
sentiment 0.390
You're right, thanks. Summit's PR went out Sunday 7:00 AM ET, the FDA issued a CRL for the BLA based on HARMONi. I missed it when I posted. Edited the post. So that's one of three on a Sunday morning; still waiting on CYTK and BioXcel.
sentiment 0.178
Share price will go down tomorrow. Buying opportunity based on their other phase 3 programs, especially HARMONI 3. I am curious to see what the CRL says. AZ had to have understood the risk of the CRL but assume they have seen data from other phase 3 programs that convinced them that ultimately the drug will receive an approval.
sentiment 0.880
SMMT got CRL
sentiment 0.000
We got the CRL, I also bought in on the AZN deal. What are your thoughts now?
sentiment 0.000
I remain bullish that the drug will receive approval. However, a full clear approval is not 100% guaranteed. I also work w AI on probabilities. There are 4 possible outcomes. A. Full approval around 50-60%; B. Conditional approval, around 20-30%; C. CRL 20%; and D. Outright rejection, 5-10%. Note these probabilities are given in ranges. The largest bullish signal was the Astra-Zeneca commmitment as there is no question that they saw data that retail does not see. Opinion only.
sentiment 0.906
